Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators

SIMPLE SUMMARY: Genome-based cancer medicine is becoming the standard of care: the patient’s tumor DNA is first analyzed to identify driver mutations, and this permits later selection of the most effective drugs. Treatment of lung cancer offers many examples. Activating mutations in the epidermal gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrocco, Ilaria, Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605519/
https://www.ncbi.nlm.nih.gov/pubmed/37894376
http://dx.doi.org/10.3390/cancers15205009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605519/
https://www.ncbi.nlm.nih.gov/pubmed/37894376
http://dx.doi.org/10.3390/cancers15205009

Ejemplares similares